Digbi Health reported mean weight loss of 18.4% at 12 months across 3,181 members taking tirzepatide alongside a personalized lifestyle program built on genetics, gut microbiome composition, blood biomarkers and continuous glucose data. The company compared this with three published U.S. tirzepatide cohorts reporting 12.4% to 16.5% mean loss over similar periods. Meal-quality scoring within the platform was reported to correlate with medication response, with each one-point increase in its Nutrient Density Score associated with roughly two additional percentage points of weight loss.
Key Points
- 18.4% mean 12-month weight loss in 3,181 tirzepatide users
- Published tirzepatide cohorts reported 12.4%–16.5% over comparable periods
- Higher meal-quality scores tracked with greater medication response
Longevity Analysis
Pharmacological appetite suppression removes a driver of excess intake, but the composition of what remains on the plate determines whether the resulting weight loss preserves lean mass, metabolic flexibility and nutrient status. Reading individual response signals — glucose variability, microbial composition, circulating markers — allows nutrition and activity to be matched to the person rather than the drug class, and the reported dose-response between meal quality and outcome points to daily adherence as the operative variable. These are company-reported comparisons against external cohorts rather than randomized data, and warrant the caution appropriate to non-contemporaneous controls.
Original published by LT Wire.